Abstrakt

New developments to optimize postprandial glucose control with insulin in patients with diabetes

Bastiaan E de Galan

Many patients with Type 1 or insulin-requiring Type 2 diabetes fail to achieve the widely recommended glycemic target of HbA1c below 7%. Insufficient control of postprandial glucose excursion plays an important role in this failure. The pharmacological profile of rapid-acting insulin analogs is still far from mimicking the physiological profile of endogenous insulin secretion. Several products are under development that aim to bring this goal closer. These developments include the use of jet injectors for insulin administration, coadministration of hyaluronidase, insulin agents that are resistant to hexamer formation, and insulin products that use an alternative route of administration. This review provides an overview of recent developments and discusses potential benefits with respect to postprandial glucose control.